Record Details

Fluvoxamina: profilo farmacoeconomico

Farmeconomia

View Archive Info
 
 
Field Value
 
Title Fluvoxamina: profilo farmacoeconomico
 
Creator Eandi, Mario
 
Subject Pharmacoeconomics; Health economics
 
Description In this study we mean to outline a brief pharmacoeconomic review of fluvoxamine, considering only its antidepressant use. Essential objective is to highlight all the variables of cost effectiveness, tolerance and safety that can lead some types of differential costs. This study analyses the epidemiology and the economic burden of depression and a pharmacoeconomic profile of fluvoxamine, with its characteristics of effectiveness, tolerance, safety and handiness. The pharmacoeconomic evaluation is conducted according to the cost minimization analysis (CMA), considering fluvoxamine, Selective Serotonine Reuptake Inhibitors (SSRI) and antidepressant tricycic as native treatments. Fluvoxamine differs from the others SSRI far the purchase cost and it’s more convenient than the antidepressant tricycic treatment, especially for long term therapy. Economic benefits can be distributed in a balanced way between the Italian national healthcare system (NACS), the society and the patients.
 
Publisher SEEd Medical Publishers
 
Date 2001-09-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier https://journals.seedmedicalpublishers.com/index.php/FE/article/view/731
10.7175/fe.v2i3.731
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 2, No 3 (2001); 175-184
2240-256X
 
Language eng
 
Relation https://journals.seedmedicalpublishers.com/index.php/FE/article/view/731/833
 
Rights Copyright (c) 2001 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0